Ps	Psoriasis
PsA	Psoriatic Arthritis
CASPAR	ClASsification criteria for Psoriatic Arthritis
RA	Rheumatoid Arthritis
Th	T helper
ROR-γt	Retinoic-acid-receptor-related Orphan Receptor-γt
HLA	Human Leukocyte Antigen
NF-κB	Nuclear Factor-Kappa B
TNF	Tumor Necrosis Factor
IFIH1	Interferon-Induced with Helicase C Domain 1
GWAS	Genome-Wide Association Studies
MTX	Methotrexate
PASI	Psoriasis Area and Severity Index
CRP	C-Reactive Protein
CXCL10	C-X-C motif chemokine Ligand 10
IBD	Inflammatory Bowel Disease
VEGF	Vascular Endothelial Growth Factor
PEAC	Pathobiology of Early Arthritis Cohort
APC	Antigen-Presenting Cells
CLA	Cutaneous Lymphocyte Antigen
ELS	Ectopic Lymphoid Structure
NK	Natural Killer
TGFβ	Transforming Growth Factor-β
IL-17R	IL-17 Receptors
JAK	Janus Kinase
STAT	Signal Transducer and Activator of Transcription
CCL20	C-C motif chemokine Ligand 20
CSF2	Colony Stimulating Factor 2
GM-CSF	Granulocyte Macrophage-Colony Stimulating Factor
NKT	Natural Killer T
ILC	Innate Lymphoid Cells
MAPK	Mitogen-Activated Protein Kinase
DC	Dendritic Cells
RANKL	Receptor Activator of Nuclear factor κB
K16	Keratin 16
IFNγ	Interferon γ
ACR	American College of Rheumatology
PGA	Physician Global Assessment
FDA	Food and Drugs Administration
DMARDs	Disease Modifying Anti-Rheumatic Drugs
NICE	National Institute for health and Care Excellence
Ust	Ustekinumab
Bri	Briakinumab
Gus	Guselkumab
Ada	Adalimumab
Ris	Risankizumab
Til	Tildrakizumab
Eta	Etanercept
Sec	Secukinumab
Ixe	Ixekizumab
Bro	Brodalumab
IGA	Investigator’s Global Assessment